Loading...
•
Dec 31, 2024
Oncology Institute Q4 2024 Earnings Report
The Oncology Institute reported fourth quarter results with strong revenue growth driven by dispensary performance but continued to post a net loss.
Key Takeaways
The Oncology Institute achieved $100 million in revenue for Q4 2024, representing a 16.9% year-over-year increase. Dispensary revenue saw significant growth, while patient services declined due to the loss of a major contract. The company reported a net loss of $13.2 million for the quarter and continues to improve operational efficiency and cash flow.
Generated $100 million in revenue, up 16.9% from Q4 2023.
Patient services revenue declined 10.6% year-over-year due to a lost contract.
Dispensary revenue increased by 72.4% year-over-year, driven by California pharmacy performance.
Reported a net loss of $13.2 million for the quarter.
Revenue by Segment
Forward Guidance
For fiscal year 2025, The Oncology Institute projects revenue between $460 million and $480 million, with improved gross profit and operational efficiency despite seasonal challenges.
Positive Outlook
- Projected 2025 revenue of $460 to $480 million.
- Expected gross profit between $73 million and $82 million for FY 2025.
- Continued growth in dispensary and value-based services.
- Operational efficiencies and cost optimizations to continue.
- Expansion into new markets and contracts expected to drive growth.
Challenges Ahead
- Anticipated Q1 2025 Adjusted EBITDA loss of $5 to $6 million due to seasonal factors.
- Industry-wide compression of margins on Part D medications.
- Loss of a large contract impacting patient services revenue.
- High SG&A expenses continue to weigh on profitability.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...